© The Author 2008. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.
Editorial |
Promoting economic value in public health
Reiner LeidlHelmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
Correspondence: Reiner Leidl, Institute for Health Economics and Health Care Management, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Postfach 1129, D-85758 Neuherberg, Germany, e-mail: leidl@helmholtz-muenchen.de
| The first 10% of the full text of this article appears below. |
In the pharmaceutical field, the term fourth hurdle has become common currency in many health systems. It means that only products that can show their cost-effectiveness will gain unrestricted access to patients. The preceding hurdles of safety, efficacy and quality have existed for several decades and have been harmonized within the European Union years ago. In the early 1990s, Australia and Canada pioneered the integration of cost-effectiveness